Literature DB >> 21573974

Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.

Marvin Rubenstein1, Courtney M P Hollowell, Patrick Guinan.   

Abstract

Antisense oligonucleotides (oligos) have been administered against in vivo and in vitro prostate cancer models employing LNCaP and PC-3 cell lines. While most oligos consist of a single mRNA binding site targeting a single gene product or those with sequence homology, our lab has developed bispecific oligos directed toward two unrelated proteins. In LNCaP cells, we initially identified bispecifics that increased the expression of prostate-specific membrane antigen (PSMA) while not affecting secreted prostate-specific antigen (PSA). We postulated that surface antigen expression is increased by bispecifics able to form double-stranded regions, acting as interferon (IFN-γ) inducers. In other systems, when induced, IFN-γ promotes cell surface antigen expression, including HLA and receptors for tumor necrosis factor. To test this hypothesis, we measured the effect of oligo treatment on both IFN-γ induction and the expression of another secreted product of differentiated prostate cells, prostatic acid phosphatase (PAP). This study initially evaluated the inhibition of in vitro propagating LNCaP cells employing mono- and bispecific oligos directed against bcl-2 (the second bispecific binding site was against the epidermal growth factor receptor). Employing RT-PCR, the expression of non-targeted proteins encoded by mRNA for PSMA, PSA, PAP, and IFN-γ was subsequently valuated. When LNCaP prostate tumor cells were incubated with oligos and compared to lipofectin-containing controls significant growth inhibition resulted. Employing RT-PCR, the levels of mRNA encoding PSMA were unexpectedly found to be elevated following treatment with the bispecific oligos but not with a monospecific directed solely against bcl-2. No differences were detected in mRNA levels encoding PSA following treatment with either oligo type. IFN-γ was significantly induced only by bispecific oligos, and PAP expression was similar to PSA. These data support the hypothesis that double strand-forming bispecific oligos induce IFN-γ that enhances cell surface PSMA expression. Expression of tumor-associated surface antigens could increase their recognition and targeting by immunologic defense mechanisms and increase the effectiveness of tumor vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21573974     DOI: 10.1007/s12032-011-9977-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  14 in total

1.  Does the prostate retain an endogenous antiviral defense system suggesting a past viral etiology for cancer?

Authors:  Marvin Rubenstein; Courtney M P Hollowell; Patrick Guinan
Journal:  Med Hypotheses       Date:  2010-11-19       Impact factor: 1.538

2.  Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.

Authors:  Marvin Rubenstein; Kenning M Anderson; Paulus Tsui; Patrick Guinan
Journal:  Med Hypotheses       Date:  2006-07-25       Impact factor: 1.538

3.  Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.

Authors:  R Y Walder; J A Walder
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

4.  Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor.

Authors:  M Tsujimoto; Y K Yip; J Vilcek
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

5.  Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.

Authors:  M Rubenstein; P Tsui; P Guinan
Journal:  Methods Find Exp Clin Pharmacol       Date:  2006-10

6.  Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.

Authors:  Marvin Rubenstein; Paulus Tsui; Patrick Guinan
Journal:  Med Hypotheses       Date:  2005       Impact factor: 1.538

7.  Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.

Authors:  Marvin Rubenstein; Paulus Tsui; Patrick Guinan
Journal:  Med Oncol       Date:  2007-10-30       Impact factor: 3.064

8.  Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.

Authors:  Marvin Rubenstein; Paulus Tsui; Patrick Guinan
Journal:  Med Oncol       Date:  2008-08-07       Impact factor: 3.064

9.  Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.

Authors:  Yelena Mirochnik; Marvin Rubenstein; Patrick Guinan
Journal:  J Drug Target       Date:  2007-06       Impact factor: 5.121

10.  Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.

Authors:  Marvin Rubenstein; Paulus Tsui; Patrick Guinan
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

View more
  5 in total

1.  In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2.

Authors:  Marvin Rubenstein; Courtney M P Hollowell; Patrick Guinan
Journal:  Ther Adv Urol       Date:  2011-12

2.  Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides.

Authors:  Marvin Rubenstein; Courtney M P Hollowell; Patrick Guinan
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

3.  Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2012-09-22

Review 4.  Emerging roles of human prostatic Acid phosphatase.

Authors:  Hoon Young Kong; Jonghoe Byun
Journal:  Biomol Ther (Seoul)       Date:  2013-01       Impact factor: 4.634

Review 5.  Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.

Authors:  Alexander Batista-Duharte; Luis Sendra; Maria José Herrero; Damiana Téllez-Martínez; Iracilda Zeppone Carlos; Salvador Francisco Aliño
Journal:  Biomolecules       Date:  2020-02-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.